Research and Markets (http://www.researchandmarkets.com/research/c7060e/stakeholder_insigh) has announced the addition of the "Stakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy" report to their offering.
The drug therapy of acute myeloid leukemia (AML) and adult acute lymphoblastic leukemia (ALL) is largely based on chemotherapy regimens that have changed little in the past few decades. Patient outcomes for both diseases remain poor, particularly for elderly and high-risk patients. As the limits of cytotoxic chemotherapy are being reached, an unmet need remains for novel, improved therapies.
Scope
- Analysis of the AML and adult ALL market based on a survey of 180 acute leukemia specialists, supported by interviews with key opinion leaders.
- Segmentation of the AML and adult ALL populations by age group and risk group, respectively
- In-depth analysis of treatment patterns, regimens prescribed and treatment outcomes for AML and adult ALL by age group and risk group, respectively
- Discussion of unmet needs and overview of late-stage pipeline drugs and marketed drugs investigated for expansion into the AML and adult ALL settings
Highlights of this title
The only molecular targeted therapy approved for use in AML is Mylotarg (gemtuzumab ozogamicin; Wyeth) but its use is limited to elderly, relapsed patients who are not candidates for other chemotherapy. A number of molecular targeted therapies are currently in development for AML but are expected to have minimal impact on patient outcomes.